Display Settings:

Format

Send to:

Choose Destination
  • Your browser version may not work well with NCBI's Web applications. More information here...

Dermatol Online J. 2009 Jul 15;15(7):15.

Adalimumab in the management of palmoplantar psoriasis.

Ghate JV, Alspaugh CD.

Palmoplantar pustular psoriasis (PPP) is an uncommon form of chronic psoriasis. Characterized by sterile, intraepidermal pustules located on the palms and soles, it is highly resistant to treatment. Our patient presented with palmar inflammation and throbbing joint pain in his hands, as well as erythematous, pustular, and micaceous scaling skin on his right foot, legs, elbows, and hands. Approximately 4 percent of his body surface area was involved and he was diagnosed with PPP after skin biopsy. After conventional therapy failed, the patient underwent treatment with adalimumab and the majority of his symptoms resolved after 16 weeks of therapy. Adalimumab may be effective for the treatment of PPP. Adalimumab, a fully human immunoglobulin G1 monoclonal antibody that binds to tumor necrosis factor, has been approved for the treatment of moderate to severe psoriasis, in the United States, Europe, and elsewhere.

PMID: 19903443 [PubMed - in process]

Publication Types

Publication Types:

Supplemental Content

Click here to read